vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
Publié le: 2024-03-13 12:00:00
Lorem ipsum dolor sit amet consectetur adipisicing elit. Accusamus quos id harum qui eos libero fugit distinctio, iste similique quibusdam

Quelques suggestions